May 31-June 03, 2024, Valencia, Spain

European Academy of Allergy and Clinical Immunology (EAACI)

June 09−11, 2023, Hamburg, Germany

European Academy of Allergy and Clinical Immunology (EAACI)

Oral icon

Long-term efficacy and safety of remibrutinib in patients with chronic spontaneousu urticaria in the Phase 3 REMIX-1 and REMIX-2 studies

M. Metz, A.M. Giménez-Arnau, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini,
E. Şavk, G. Sussman, R. Szalewski, I. Walecka Herniczek, H. Windom, S. Haemmerle, K. Lheritier, Paula G.P. Machado, E-D. Martzloff, N. Seko, P. Wang, A. Zharkov, M. Maurer
Abstract Oral presentation
Oral icon

Effect of remibrutinib on disease activity in patients with chronic spontaneous urticaria: post hoc analysis of Phase 3 REMIX-1 and REMIX-2 studies

M. Maurer, F. Berard, E. Savk, M. Hide, I.A. Neves, K. Lheritier, N. Chapman-Rothe, S. Haemmerle, A.M. Giménez-Arnau
Abstract Oral presentation
Oral icon

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria: Results from the Phase 3 studies

A.M. Giménez-Arnau, M. Hide, M.Lebwohl, G. Sussman, S. Saini, S. Haemmerle, N. Seko, P. Wang, E-D. Martzloff, M. Maurer
Abstract Oral presentation
Oral icon

Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the Phase 3 REMIX-1 and REMIX-2 studies​

P. Staubach, S. Saini, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Sussman, S. Haemmerle,
K. Lheritier, E-D. Martzloff, A. Zharkov, M. Maurer
Abstract Poster
Oral icon

Physicians’ prescribing patterns and perceptions of treatments for chronic spontaneous urticaria: Real world data from Urticaria Voices​ study

J.A. Bernstein, K. Weller, M-M.Balp, J. McCarthy, P. Laires, P. Saraswat, T. Raftery, T.A. Winders
Abstract Flash Talk
Oral icon

Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study​

T.A. Winders, J.A. Bernstein, M-M. Balp, J. McCarthy, P. Laires, P. Saraswat, T. Raftery, K. Weller
Abstract Flash Talk
Oral icon

Remibrutinib (LOU064) treatment improves hive severity in patients with chronic spontaneous urticaria: Findings from a Phase 2b study

A. Gimenez-Arnau, K. Hayama, V. Jain, K. Sitz, K. Lheritier, I. Nikolaev, P. Walsh, S. Haemmerle, M. Maurer
Abstract Oral presentation
Oral icon

Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from a 52-week phase 2b extension study

A. Gimenez-Arnau, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, S. Hugot, M. Wells, A. Zharkov, W. Carr
Abstract Oral presentation
Oral icon

Remibrutinib (LOU064) treatment improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Phase 2b study results

M. Metz, A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev, A. Giménez-Arnau, M. Maurer
Abstract Oral presentation
Oral icon

Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the Phase 2b study

M. Maurer, A. Giménez-Arnau, V. Jain, A. Reich, CE. Ortmann, P. Walsh, S. Haemmerle
Abstract Poster
Oral icon

Efficacy, safety, and tolerability of remibrutinib (LOU064) in CSU patients: Study design of Phase 3b extension trial

M. Maurer, A. Giménez-Arnau, S. Saini, M. Lebwohl, G. Sussman, M. Hide, K. Lheritier, A. Zharkov, S. Bhat, L. Wei, ED. Martzloff, S. Haemmerle
Abstract Poster
Oral icon

Divergent Patients' and Physicians' Perceptions of Chronic Urticaria Disease Control: An Urticaria Voices Study Outcome

PA. Laires, MM. Balp, K. Weller, TA. Winders, JA. Bernstein, M. Dricu, S. Flierl, L. Christen, N. Janssens, S. Smeets
Abstract Poster
Oral icon

Prevalence and overall disease burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, and United Kingdom)

MM Balp, K Krupsky, BL Balkaran, S Gupta, C Lienhard, D Patil, RK Kohli, JM Rodriguez Barrios, A Romero, F Tétart, J Reed, T El-Shanawany
Abstract Oral presentation
Novartis logo
Cookie Settings
© Copyright 2023 Novartis Pharma AG